Moreover, given the role of NPC1L1 as the target of ezetimibe, exploring the use of ezetimibe as an adjuvant therapy in RCC could be one potential approach to inhibiting tumor progression and metastasis. This evidence concerns the gene NPC1L1 and renal cell carcinoma.